GHRP-2

Mechanism

GHS-R1a agonist that can raise GH with cortisol/prolactin spillover.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• GH pulse amplification
• Appetite stimulation
• Legacy comparator

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

~0,55+/-0,14 h (human) — study. Frontiers in endocrinology 2026; healthy humans.

Storage

Lyophilised: Stable at room temperature ~3 weeks; store desiccated below -18C. Reconstituted: Reconstitute in sterile 18 Mohm-cm H2O at >=100 ug/mL; 4C for 2-7 days; below -18C for future use; 0.1% HSA/BSA for long term. — source. ProSpec technical datasheet. Supplier handling recommendation for research-grade lyophilate, not a per-compound stability study.

In sport (WADA 2026)

Prohibited, at all times — named S2.2.4 (GHRPs: GHRP-2 (pralmorelin)). the list

The half-life on file is 33 min. On the schedule this record states — daily — each dose has fallen to under 0.1% of its own peak by the time the next is given. Nothing accumulates, and there is no loading phase to run.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Reported adverse effects

• Increased appetite

  Commononset: Post-injectionreported reversible

• Transient cortisol and prolactin elevation at higher doses

  Dose-dependentonset: Post-injectionreported reversible

Literature on file 5

• human case series
  Pituitary dysfunction in trans-sellar encephalocele: a two-case report and a literature review. graded on: a case report or series — “case report”
• review or editorial
  The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• animal in vivo
  Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions. graded on: an animal model — read from the indexed abstract — “mice”
• human observational
  Endocrine disorders in pediatric medulloblastoma survivors treated with X-ray or proton beam therapy: a single-institution retrospective study. graded on: an observational human design — “retrospective”
• animal in vivo
  Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism. graded on: an animal model — read from the indexed abstract — “mouse”

What is circulated not evidence 3

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose ubiquitous agrees with the record

  100-300 mcg one to three times daily is circulated, with 100 mcg once before bed as the beginner protocol.

  100 to 300 mcg per injection, administered subcutaneously one to three times daily

  On the record Dosing on file is 100-300 mcg daily; per-injection multi-dosing up to 900 mcg/day exceeds the record, and no bedtime-timing record exists.

  Source 1

• unverified community data benefit common nothing on file either way

  GHRP-2 is circulated as producing higher peak GH than GHRP-6 with less hunger, making it the cutting-phase choice.

  moderate stimulation of the ACTH-cortisol axis and prolactin secretion

  On the record The record holds GH pulse amplification, appetite stimulation and a legacy-comparator role; no head-to-head ranking against GHRP-6 is on file.

  Source 1 · Source 2

• unverified community data stacking common nothing on file either way

  Stacking 100-200 mcg with CJC-1295 simultaneously is circulated as amplifying GH output two to three times beyond either alone.

  100 to 200 mcg of each peptide administered simultaneously

  On the record No stacking record exists on file for GHRP-2.

  Source 1

Identity

PubChem CID 6918245 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 6918245, the identifier on this record.

Molecular weight

818.0

Molecular formula

C45H55N9O6

CAS number

158861-67-7

PubChem CID

6918245

InChI key

HRNLPPBUBKMZMT-RDRUQFPZSA-N

Sequence

AXAWFK

SMILES

C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N

InChI

InChI=1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1

Classified as

Ghrelin Receptor Agonismmechanism

This is the mechanism behind the compounds usually filed as secretagogues, and it explains why appetite effects appear in the same records as growth hormone effects rather than as an unrelated aside.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Intranasalroute

A nasal device delivers a fixed volume per spray, so concentration rather than syringe volume sets the amount per spray, and a mass figure on a record is not usable until you know how many actuations it was divided across.

Intravenousroute

A large share of the pharmacokinetic numbers attached to peptide records, half-life in particular, come from intravenous studies and often from animals. Those numbers describe an intravenous curve and do not transfer unchanged to a depot under the skin.

Also called

• GHRP-2
• Pralmorelin
• growth hormone-releasing peptide-2
• pralmorelinum

Listed prices 120

What 66 shops we track listed for GHRP-2, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record